These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19268363)

  • 1. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Morris KL; Adams JA; Liu Yin JA
    Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laromustine: the return of alkylators to non-myeloablative therapy of AML.
    Giles FJ
    Leuk Res; 2009 Aug; 33(8):1022-3. PubMed ID: 19328547
    [No Abstract]   [Full Text] [Related]  

  • 3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
    Gu C; Ye T; Wells RA
    Leuk Res; 2006 Nov; 30(11):1447-51. PubMed ID: 16704876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
    Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
    Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Zheng LM; Li Z; Liu L; Song BL; King I
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
    Jordheim LP; Plesa A; Dreano M; Cros-Perrial E; Keime C; Herveau S; Demangel D; Vendrell JA; Dumontet C
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):97-105. PubMed ID: 20844879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
    Giles F; Verstovsek S; Faderl S; Vey N; Karp J; Roboz G; Khan KD; Cooper M; Bilgrami SF; Ferrant A; Daenen S; Karsten V; Cahill A; Albitar M; Kantarjian H; O'Brien S; Feldman E
    Leuk Res; 2006 Dec; 30(12):1591-5. PubMed ID: 16574225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laromustine (cloretazine).
    Vey N; Giles F
    Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
    Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
    Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
    Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of daunorubicin and cytarabine on cell line NB4].
    Luo ZG; Zhong L; Chen FY; Wang HR; Ouyang RR
    Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):247-9. PubMed ID: 17877202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.